PCSK9 and Hypercholesterolemia: Indeed, despite aggressive treatment of hypercholesterolaemia using statins and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, over one third of patients still have hs-CRP levels > 3 mg/L which is associated with an increased risk of future major adverse cardiac events (MACE) [7].